We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Endogenous Interference Impairs Arterial Blood Gas Analysis

By LabMedica International staff writers
Posted on 20 Mar 2012
Print article
Blood samples that show hemolysis, lipemia, or icterus may be unsuitable for arterial blood gas analysis (ABG) as these indices affect the results.

The modern ABG analyzers enables rapid analysis of traditional blood gas elements such as pH, partial pressure of carbon dioxide (pCO2) and oxygen partial pressure (pO2), and oxygen saturation as well as clinical chemistry parameters, all of which rely on the quality of the specimens.

Scientists at the University of Verona (Italy) analyzed 478 ABG specimens received in their laboratory throughout a two-month study period. The serum indices (SI) were assessed after all routine and stat samples referred for ABG analysis to the clinical laboratory using RAPIDPoint 400/405 Systems, Arterial Blood Gas Analyzer were completed. The SI of plasma was then assessed on the Cobas C501 after centrifugation. Interference cut-off values were 60 for Hemolysis Index (HI, i.e., cut-off of visible hemolysis), 30 for Lipemia Index (LI, i.e. Lipemic index is determined by the turbidity qualitatively with no units) and two for Icteric Index (II).

Out of a total of 478 ABG specimens received in the laboratory throughout the two month study period, 132 (27.6%) displayed at least one SI exceeding the cut-off. This could be further categorized as 44/162 (27.2%) from the emergency department, and 88/316, (28.6%) from the clinical wards. In particular 17 samples (4%) were characterized by HI exceeding 60, 52 samples (11%) by a LI exceeding 30, and 63 (13%) by II exceeding two. The frequency of hemolyzed specimens referred from the emergency department was double that of samples referred from the clinical wards.

The RAPIDPoint 400/405 Systems, Arterial Blood Gas Analyzer is a product of Siemens Medical Solutions (Munich, Germany) and the Cobas C501 is manufactured by Roche (Basle, Switzerland). The authors concluded that that a significant number of AGB specimens sent to their laboratory were characterized by elevated values of the SI, which could make them unreliable for testing. In particular, the frequency of HI greater than 60 was remarkably higher for samples referred from the emergency department than in those from the clinical wards, thereby confirming the trend already observed for clinical chemistry, immunochemistry, and coagulation testing. The study was published in the March 2012 issue of the journal Clinical Biochemistry.

Related Links:

University of Verona
Siemens Medical Solutions
Roche


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.